Vaccination for Coronavirus Disease 2019 ( COVID ‐19) and Relationship to Osteoporosis Care: Current Evidence and Suggested Approaches
出版年份 2021 全文链接
标题
Vaccination for Coronavirus Disease 2019 (
COVID
‐19) and Relationship to Osteoporosis Care: Current Evidence and Suggested Approaches
作者
关键词
-
出版物
JOURNAL OF BONE AND MINERAL RESEARCH
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2021-04-09
DOI
10.1002/jbmr.4304
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Raloxifene as a treatment option for viral infections
- (2021) Subin Hong et al. JOURNAL OF MICROBIOLOGY
- Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized Trial
- (2020) Andrew Grey et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- An interactive web-based dashboard to track COVID-19 in real time
- (2020) Ensheng Dong et al. LANCET INFECTIOUS DISEASES
- Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis
- (2020) Sara Kaveh et al. CLINICAL RHEUMATOLOGY
- Impact of the COVID-19 Pandemic on an Emergency Traumatology Service: Experience at a Tertiary Trauma Centre in Spain
- (2020) Jorge H. Nuñez et al. INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
- Osteoporosis Management in the Era of COVID ‐19
- (2020) Elaine W Yu et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis
- (2020) Zhaohai Zheng et al. JOURNAL OF INFECTION
- Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
- (2020) Feng-Cai Zhu et al. LANCET
- The Untold Toll — The Pandemic’s Effects on Patients without Covid-19
- (2020) Lisa Rosenbaum NEW ENGLAND JOURNAL OF MEDICINE
- Vitamin-D and COVID-19: do deficient risk a poorer outcome?
- (2020) Fiona Mitchell Lancet Diabetes & Endocrinology
- MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-19
- (2020) John P. Bilezikian et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Epidemiologic characteristics of traumatic fractures during the outbreak of coronavirus disease 2019 (COVID-19) in China: A retrospective & comparative multi-center study
- (2020) Hongzhi Lv et al. INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
- Osteoporotic Fractures in the Time of COVID ‐19
- (2020) Timothy Bhattacharyya JOURNAL OF BONE AND MINERAL RESEARCH
- Vitamin D Supplementation During the COVID-19 Pandemic
- (2020) Darko Siuka et al. MAYO CLINIC PROCEEDINGS
- Managing fragility fractures during the COVID-19 pandemic
- (2020) Nicola Napoli et al. Nature Reviews Endocrinology
- The Covid-19 Vaccine-Development Multiverse
- (2020) Penny M. Heaton NEW ENGLAND JOURNAL OF MEDICINE
- COVID-19 Vaccine: A comprehensive status report
- (2020) Simran Preet Kaur et al. VIRUS RESEARCH
- Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions
- (2020) Josep Blanch-Rubió et al. Aging-US
- Nutritional status, diet and viral respiratory infections: perspectives for severe acute respiratory syndrome coronavirus 2
- (2020) Ana Heloneida de Araújo Morais et al. BRITISH JOURNAL OF NUTRITION
- Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS
- (2020) Elena Tsourdi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- State of Fragility Fractures Management during the COVID-19 Pandemic
- (2020) Umberto Tarantino et al. International Journal of Environmental Research and Public Health
- Sarcopenia during COVID-19 lockdown restrictions: long-term health effects of short-term muscle loss
- (2020) Richard Kirwan et al. GeroScience
- Correlates of protection against SARS-CoV-2 in rhesus macaques
- (2020) Katherine McMahan et al. NATURE
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Denosumab vs risedronate in glucocorticoid-induced osteoporosis: final results of a 24-month randomized, double-blind, double-dummy trial
- (2019) Kenneth G. Saag et al. Arthritis & Rheumatology
- Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors
- (2019) Elena Gonzalez-Rodriguez et al. BREAST CANCER RESEARCH AND TREATMENT
- Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial
- (2019) Robert Coleman et al. LANCET ONCOLOGY
- Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study
- (2018) Michael R McClung et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Fracture Prevention with Zoledronate in Older Women with Osteopenia
- (2018) Ian R. Reid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting
- (2017) Arthur N. Lau et al. JOURNAL OF RHEUMATOLOGY
- 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
- (2017) Henry G Bone et al. Lancet Diabetes & Endocrinology
- The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)
- (2015) Dennis M. Black et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
- (2015) Alison T. Stopeck et al. SUPPORTIVE CARE IN CANCER
- Risk of Hospitalized Infection Among Rheumatoid Arthritis Patients Concurrently Treated With a Biologic Agent and Denosumab
- (2015) Jeffrey R. Curtis et al. Arthritis & Rheumatology
- Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: A comparison with a 2.5mg once-daily dosage regimen
- (2013) Hiroshi Hagino et al. BONE
- TNF-α mediates the stimulation of sclerostin expression in an estrogen-deficient condition
- (2012) Beom-Jun Kim et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Five years of anti-resorptive activity after a single dose of zoledronate — Results from a randomized double-blind placebo-controlled trial
- (2012) Andrew Grey et al. BONE
- Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration
- (2011) Maurizio Rossini et al. JOURNAL OF BONE AND MINERAL RESEARCH
- The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
- (2011) Dennis M Black et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Characterization of and Risk Factors for the Acute-Phase Response after Zoledronic Acid
- (2010) I. R. Reid et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pro-Inflammatory Cytokines TNF-Related Weak Inducer of Apoptosis (TWEAK) and TNFα Induce the Mitogen-Activated Protein Kinase (MAPK)-Dependent Expression of Sclerostin in Human Osteoblasts*
- (2009) Cristina Vincent et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of Teriparatide Treatment and Discontinuation in Postmenopausal Women and Eugonadal Men with Osteoporosis
- (2009) Benjamin Z. Leder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation